Heterogeneity of PD-L1 expression and relationship with biology of NSCLC
M Bassanelli, S Sioletic, M Martini, S Giacinti… - Anticancer …, 2018 - ar.iiarjournals.org
Immunotherapy with monoclonal antibodies against programmed cell death (PD-1), such as
nivolumab and pembrolizumab, has significantly improved the survival of patients with …
nivolumab and pembrolizumab, has significantly improved the survival of patients with …
[HTML][HTML] Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer
Introduction Programmed death-ligand 1 (PD-L1) is used as a biomarker for anti–
programmed cell death protein-1 (PD-1) or anti-PD-L1 immunotherapies in NSCLC. We …
programmed cell death protein-1 (PD-1) or anti-PD-L1 immunotherapies in NSCLC. We …
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
O Bylicki, N Paleiron, J Margery, F Guisier… - Targeted Oncology, 2017 - Springer
Immune checkpoint inhibitors, notably antibodies targeting programmed death–1 (PD-1) and
programmed death ligand–1 (PD-L1), have modified the management of patients with …
programmed death ligand–1 (PD-L1), have modified the management of patients with …
[HTML][HTML] Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
G Guaitoli, M Tiseo, M Di Maio, L Friboulet… - … lung cancer research, 2021 - ncbi.nlm.nih.gov
Background Treatment of oncogene-addicted non-small cell lung cancer (NSCLC) has been
changed by the advent of tyrosine kinase inhibitors (TKIs). Albeit great benefits are achieved …
changed by the advent of tyrosine kinase inhibitors (TKIs). Albeit great benefits are achieved …
[HTML][HTML] Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis
B Lan, C Ma, C Zhang, S Chai, P Wang, L Ding… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Objective To assess the association between PD-L1 expression and driver gene mutations
in patients with non-small-cell lung cancer (NSCLC). Method We performed a meta-analysis …
in patients with non-small-cell lung cancer (NSCLC). Method We performed a meta-analysis …
[HTML][HTML] The combination of checkpoint immunotherapy and targeted therapy in cancer
N Karachaliou, M Gonzalez-Cao, A Sosa… - Annals of …, 2017 - ncbi.nlm.nih.gov
The therapeutic possibilities for patients with metastatic melanoma have changed due to the
development of targeted therapies that inhibit oncogenic signaling pathways as well as …
development of targeted therapies that inhibit oncogenic signaling pathways as well as …
[PDF][PDF] An efficient combination immunotherapy for primary liver cancer by harmonized activation of innate and adaptive immunity in mice
Immunotherapy with checkpoint inhibitors for liver cancer, while active in many clinical trials
worldwide, may have uncertain outcomes due to the unique immunotolerant …
worldwide, may have uncertain outcomes due to the unique immunotolerant …
The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer
S Zhang, X Bai, F Shan - International Immunopharmacology, 2020 - Elsevier
Recently, immunotherapy has evolved into a true treatment modality with the approval of PD-
1 and PD-L1 inhibitors as the standard care for first-line treatment in patients with non-small …
1 and PD-L1 inhibitors as the standard care for first-line treatment in patients with non-small …
Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in …
Q Zheng, Y Huang, X Zeng, X Chen, S Shao… - Journal of Cancer …, 2021 - Springer
Purpose The study aimed to evaluate the clinicopathological and molecular profiles
associated with programmed death ligand 1 (PD-L1) expression in non-small cell lung cell …
associated with programmed death ligand 1 (PD-L1) expression in non-small cell lung cell …
A novel mTORC1/2 inhibitor (MTI-31) inhibits tumor growth, epithelial–mesenchymal transition, metastases, and improves antitumor immunity in preclinical models of …
Q Zhang, Y Zhang, Y Chen, J Qian, X Zhang… - Clinical Cancer Research, 2019 - AACR
Purpose: We aimed to investigate efficacy and mechanism of MTI-31 (LXI-15029), a novel
mTORC1/mTORC2 inhibitor currently in human trial (NCT03125746), in non–small cell lung …
mTORC1/mTORC2 inhibitor currently in human trial (NCT03125746), in non–small cell lung …